|
Canada-0-LABORATORIES ไดเรกทอรีที่ บริษัท
|
ข่าว บริษัท :
- Rechallenge therapy versus tyrosine kinase inhibitor (TKI . . .
Abstract Currently, the standard third-line treatment options for advanced metastatic colorectal cancer (mCRC) include regorafenib, fruquintinib, and trifluridine tipiracil (TAS-102), but these drugs have limited clinical efficacy This study aims to evaluate the efficacy and survival outcomes of tyrosine kinase inhibitor (TKI) versus chemotherapy rechallenge in third-line treatment for
- Lost in translation: Revisiting the use of tyrosine kinase . . .
Patients with advanced or metastatic colorectal cancer ( (m)CRC) have limited effective treatment options resulting in high mortality rates A better understanding of the molecular basis of this disease has led to growing interest in small molecule tyrosine kinase inhibitors (TKIs) for its treatment
- Zanzalintinib Atezolizumab Improves CRC Survival, Expands TKI . . .
New trial results reveal zanzalintinib and atezolizumab significantly enhance survival in metastatic colorectal cancer, marking a breakthrough in treatment options
- RETRACTED ARTICLE: Rechallenge therapy versus tyrosine kinase . . .
Colorectal cancer (CRC) is the third most common cause of cancer and the second most common cause of cancer-related death worldwide At least 50% of patients will experience metastasis, with the
- Combination IO TKI Strategies in Metastatic Colorectal Cancer
A comprehensive review on combination strategies with immune checkpoint and tyrosine kinase inhibitors in patients with metastatic colorectal cancer
- Quality of life, effectiveness, and compliance of . . .
Abstract e15557 Background: Fruquintinib, an antiangiogenic tyrosine kinase inhibitor (TKI), has demonstrated its significant survival benefits in metastatic colorectal cancer (mCRC) patients in both China and global phase III trials (FRESCO and FRESCO-2), but data on patients' health-related quality of life (HRQoL) was rare
- 96P Tyrosine kinase inhibitor (TKI) plus PD-1 blockade in TKI . . .
96P Tyrosine kinase inhibitor (TKI) plus PD-1 blockade in TKI-responsive MSS pMMR metastatic colorectal adenocarcinoma (mCRC): Updated results of TRAP study J Zhang 1 ∙ Q Dong
- Treatment Combinations Based in Immune Checkpoint Inhibitors . . .
Patients with heavily pretreated microsatellite stable metastatic colorectal cancer (CRC) had survival benefits after using combinations based in immune checkpoint inhibitors
- What Is Metastasis? Cancer Spread, Detection, and Treatment
Learn how cancer spreads to other parts of the body, how metastasis is detected, and what modern treatment options exist for metastatic cancer
- Tumor Debulking in Combination With Chemotherapy in . . .
This randomized clinical trial examines whether tumor debulking added to palliative chemotherapy improves survival of patients with multiorgan metastatic colorectal cancer
|
|